User login
Key clinical point: Fixed-duration glofitamab treatment led to durable complete responses and a grade ≥3 adverse event (AE) rate of >50% in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Major finding: At a median follow-up of 12.6 months, 39% (95% CI 32%-48%) and 52% (95% CI 43%-60%) of patients achieved complete and objective responses, respectively. The median time to a complete response was 42 (95% CI 42-44) days; 78% of patients with a complete response continued to be in remission at 12 months. The grade ≥3 AE rate was 62%.
Study details: This phase 2 part of a phase 1-2 study included 155 adult patients with relapsed/refractory DLBCL previously treated with ≥2 lines of therapy who received obinutuzumab pretreatment followed by fixed-duration glofitamab monotherapy for 12 cycles.
Disclosures: This study was funded by F. Hoffmann-La Roche. Some authors reported ties with various organizations, including F. Hoffmann-La Roche. Two authors declared being employees of and holding stock or stock options in F. Hoffmann-La Roche.
Source: Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231 (Dec 11). Doi: 10.1056/NEJMoa2206913
Key clinical point: Fixed-duration glofitamab treatment led to durable complete responses and a grade ≥3 adverse event (AE) rate of >50% in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Major finding: At a median follow-up of 12.6 months, 39% (95% CI 32%-48%) and 52% (95% CI 43%-60%) of patients achieved complete and objective responses, respectively. The median time to a complete response was 42 (95% CI 42-44) days; 78% of patients with a complete response continued to be in remission at 12 months. The grade ≥3 AE rate was 62%.
Study details: This phase 2 part of a phase 1-2 study included 155 adult patients with relapsed/refractory DLBCL previously treated with ≥2 lines of therapy who received obinutuzumab pretreatment followed by fixed-duration glofitamab monotherapy for 12 cycles.
Disclosures: This study was funded by F. Hoffmann-La Roche. Some authors reported ties with various organizations, including F. Hoffmann-La Roche. Two authors declared being employees of and holding stock or stock options in F. Hoffmann-La Roche.
Source: Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231 (Dec 11). Doi: 10.1056/NEJMoa2206913
Key clinical point: Fixed-duration glofitamab treatment led to durable complete responses and a grade ≥3 adverse event (AE) rate of >50% in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).
Major finding: At a median follow-up of 12.6 months, 39% (95% CI 32%-48%) and 52% (95% CI 43%-60%) of patients achieved complete and objective responses, respectively. The median time to a complete response was 42 (95% CI 42-44) days; 78% of patients with a complete response continued to be in remission at 12 months. The grade ≥3 AE rate was 62%.
Study details: This phase 2 part of a phase 1-2 study included 155 adult patients with relapsed/refractory DLBCL previously treated with ≥2 lines of therapy who received obinutuzumab pretreatment followed by fixed-duration glofitamab monotherapy for 12 cycles.
Disclosures: This study was funded by F. Hoffmann-La Roche. Some authors reported ties with various organizations, including F. Hoffmann-La Roche. Two authors declared being employees of and holding stock or stock options in F. Hoffmann-La Roche.
Source: Dickinson MJ et al. Glofitamab for relapsed or refractory diffuse large B-cell lymphoma. N Engl J Med. 2022;387(24):2220-2231 (Dec 11). Doi: 10.1056/NEJMoa2206913